title: 18F-FDG, as a single imaging agent in assessing cancer, shows the ongoing biological phenomena in many domains: do we need additional tracers for clinical purposes?
authors.affiliation: aDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands bDepartment of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA cDepartment of Nuclear Medicine, PET/CT Centre, Radiology, Interventional Radiology NeuroRadiology, Medical Physics, Clinical Laboratory, Biomarkers Laboratory, Pathology, Microbiology, 'Santa Maria della Misericordia' Hospital, Rovigo, Italy dDepartment of Nuclear Medicine, Odense University Hospital eInstitute of Clinical Research, University of Southern Denmark, Odense, Denmark.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Kwee
authors.forename: Saeid
authors.initials: S
authors.lastname: Gholami
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Werner
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.forename: Abass
authors.initials: A
authors.lastname: Alavi
authors.forename: Poul F
authors.initials: PF
authors.lastname: Høilund-Carlsen
mesh_terms: D049109:Cell Proliferation; D003952:Diagnostic Imaging / Q000379:methods*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000473:pathology; D009389:Neovascularization, Pathologic; D049268:Positron-Emission Tomography; D011849:Radioactive Tracers
chemical_list: D011849:Radioactive Tracers; D019788:Fluorodeoxyglucose F18